Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo

Cho, Hyun‐Dong; Moon, Kwang-Deog; Park, Ki-Hun; Lee, Yong-Suk; Seo, Kwon‐Il

doi:10.1016/j.fct.2018.09.025

Cited by 22 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The VEGF release may accelerate cell migration (Mohsen, Hatef, Hamid, Ali, & Ghasem, ; Torio‐Padron et al, ). However, it seems that keeping VEGF in the scaffold supports vascularization because it not only enhances the proliferation of cells (Carpenter et al, ; Zhou et al, ), but also regulates the interaction between stem cells and ECs (such as directional differentiation of stem cells induced by ECs and pore size in the scaffold) and promotes angiogenesis (Adibfar et al, ; Cho, Moon, Park, Lee, & Seo, ; Zhou et al, ). Thus, in the present study, we designed two kinds of nanoparticles to load SDF‐1 and VEGF, respectively.…”

Section: Discussionmentioning

confidence: 99%

An injectable scaffold based on temperature‐responsive hydrogel and factor‐loaded nanoparticles for application in vascularization in tissue engineering

Zhao

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

Controlled release of functional factors contributes to target migration of therapeutic cells and plays a crucial role in the in situ vascularization of tissue repair and regeneration. A biomedical application requires the selective release of multiple factors which will guide the synergy of the cells. Here, we developed an injectable system based on a temperature-responsive hydrogel and stromal cell-derived factor-1 (SDF-1)/vascular endothelial growth factor (VEGF) loaded into two types of nanoparticles to induce migration and rapid proliferation of mesenchymal stem cells (MSCs) and endothelial cells (ECs) via selective SDF-1/VEGF release. Series of in vitro and in vivo experiments demonstrate that our composited system can accurately guide MSCs and ECs for vascularization. In addition, the properties of the nanoparticles and hydrogel, including micro/nanoscales, characteristic of charge, and biocompatibility, played crucial roles for the selective release and cells behavior (target migration and rapid proliferation).

show abstract

Section: Discussionmentioning

confidence: 99%

An injectable scaffold based on temperature‐responsive hydrogel and factor‐loaded nanoparticles for application in vascularization in tissue engineering

Zhao

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…To identify chemotactic migration of HUVECs, wound‐healing assay was used (Cho et al, ). HUVECs were seeded in 24‐well plates, and the confluent monolayer was wounded using blue pipette tips to produce cross scratches.…”

Section: Methodsmentioning

confidence: 99%

Inhibitory Effects of Pectinase‐Treated Prunus Mume Fruit Concentrate on Colorectal Cancer Proliferation and Angiogenesis of Endothelial Cells

Cho

Kim

Won

et al. 2019

Journal of Food Science

View full text Add to dashboard Cite

Pectinase is a well‐known enzyme used in the food processing industry to produce fruit juice and concentrate. This study evaluated the anticancer and antiangiogenesis activities of pectinase‐treated Prunus mume fruit concentrate (PC) and its phenolic components. PC treatment (250 to 1,000 µg/mL) resulted in decreased proliferation of SW480 human colorectal cancer cells through S‐phase cell cycle arrest; however, equivalent concentrations of PC did not show toxicity toward CRL‐1539 colon normal cells. Furthermore, PC‐induced caspase‐dependent apoptosis in SW480 cells, which was characterized by accumulation of apoptotic cell population, cell shrinkage, formation of apoptotic bodies, upregulation of proapoptotic Bax, cleaved PARP, caspase‐3, caspase‐8, and caspase‐9, and downregulation of antiapoptotic Bcl‐2. Antiangiogenesis effects of PC were assessed using human umbilical vein endothelial cells (HUVECs). We found that PC did not inhibit HUVECs proliferation at concentrations of 500 to 1,500 µg/mL. In addition, treatment with PC at nontoxic concentrations (500 to 1,000 µg/mL) blocked vascular endothelial growth factor induced cell migration, invasion, capillary‐like tube formation, and angiogenesis from rat aortic rings. HPLC‐PDA analysis showed that there were at least four different phenolics including 5‐HMF, neochlorogenic acid, protocatechuic acid, and syringic acid. Taken together, these results indicated that PC could be used as a good source of phenolic compounds with selective anticancer and antiangiogenesis activities. Practical Application Pectinases are one of the well‐known enzyme used in the part of food processing. Treatment of pectinase is a useful strategy to reduce viscosity, turbidity, and pulp particles in the production of fruit juice, extract, and concentrate. In the present study, we found that pectinase‐treated P. mume fruit concentrate significantly suppresses colorectal cancer proliferation and angiogenesis of human umbilical vein endothelial cells. The significance of our findings is that pectinase‐treated P. mume concentrate may be used as a commercial functional food material to inhibit colorectal cancer and angiogenesis.

show abstract

“…VEGFR2 is the receptor with the strongest binding affinity to VEGF-A and has an important role in signal transmission. In addition, the expression levels of VEGFR2 show a crucial role in the process of angiogenesis (50). Moreover, previous studies also suggested that higher expression levels of VEGFR2 in tumor cells were associated with a higher likelihood for tumor cells to relapse and metastasize in gastric cancer and epithelial cancer (51,52).…”

Section: Rs2071559 Genotype Status N (%) ---------------------------mentioning

confidence: 98%

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism

Yan

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The aims of the present study were to investigate the clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma (EOC) who have progressed after standard regimens, and to analyze the vascular endothelial growth factor receptor 2 (VEGFR2) rs2071559 polymorphism. A total of 118 patients with advanced EOC who received apatinib treatment were included in the study. Tumor response was evaluated using progression-free survival (PFS) and overall survival (OS) time, and safety data were documented. Additionally, peripheral blood and peripheral blood mononuclear cell (PBMC) specimens from the patients with EOC were collected to perform the genotyping of genetic polymorphism and assess the mRNA expression of VEGFR2, respectively. The objective response rate across the 118 patients with advanced EOC was 38.98%, the disease control rate was 63.56%, the median PFS time was 4.65 months and the median OS time was 15.10 months. Regarding the polymorphism analysis, the prevalence of rs2071559 in VEGFR2 among the 118 patients with advanced EOC was recorded as the TT genotype in 72 cases (61.02%), TC genotype in 41 cases (34.75%) and CC genotype in 5 cases (4.23%), and the minor allele frequency of rs2071559 was 0.22. The distribution of the three genotypes was in accordance with the Hardy-Weinberg equilibrium (P=0.781). TC and CC genotypes were merged in the subsequent analysis. The prognosis analyses suggested that the median PFS time of patients with the TC/CC genotype and the TT genotype was 3.10 and 5.40 months, respectively (P=0.015). Moreover, the median OS time of the two genotypes was 12.60 and 17.50 months, respectively (P=0.009). However, no association was noted between genotype status of the polymorphism and adverse reactions. Additionally, the mRNA expression analysis indicated that the mRNA expression levels of VEGFR2 in PBMC specimens were significantly different between TT and TC/CC genotypes (P<0.001). The present study suggested that the clinical outcomes of patients with advanced EOC, who progressed after standard regimens and received apatinib treatment, might be influenced by the VEGFR2 rs2071559 polymorphism.

show abstract

Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo

Cited by 22 publications

References 38 publications

An injectable scaffold based on temperature‐responsive hydrogel and factor‐loaded nanoparticles for application in vascularization in tissue engineering

An injectable scaffold based on temperature‐responsive hydrogel and factor‐loaded nanoparticles for application in vascularization in tissue engineering

Inhibitory Effects of Pectinase‐Treated Prunus Mume Fruit Concentrate on Colorectal Cancer Proliferation and Angiogenesis of Endothelial Cells

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism

Contact Info

Product

Resources

About